← Every company
Dana Inc Patents
What Dana Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
DAN on carbonthat →Filings on file
58
Granted
0
Still pending
58
Filed under
11 names
58 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| COMPOSITIONS AND METHODS FOR TREATING CANCER WITH INTERFERON-OMEGA AND ANALOGS THEREOFA61P 35/00, A61K 38/21, A61K 47/6851, A61K 47/6813, C07K 14/555, C07K 16/2803, C07K2319/30, G01N 33/5011, G01N 33/5047, G01N 33/5055, G01N2333/555, G01N2510/00, G01N2800/52, A61K2300/00Filed as Dana-Farber Cancer Institute, Inc.2026-07-21Kipp Weiskopf | pending |
| COMPOSITIONS AND METHODS FOR ENRICHMENT OF NUCLEIC ACIDS USING LIGHT-MEDIATED CROSS-LINKINGC12Q 1/6858, C12Q 1/6806Filed as Dana-Farber Cancer Institute, Inc.2026-07-06Ka Wai Leong | pending |
| VACCINE COMPOSITIONS AND METHODS FOR RESTORING NKG2D PATHWAY FUNCTION AGAINST CANCERSFiled as Dana-Farber Cancer Institute, Inc.2026-06-08Glenn Dranoff | pending |
| POTENT AND SELECTIVE IRREVERSIBLE INHIBITORS OF IRAK1A61K 45/06, C07D 401/14, A61P 35/00, C07D 401/04, C07D 401/12, C07D 405/14, C07D 413/14Filed as Dana-Farber Cancer Institute, Inc.2026-05-26John M. Hatcher | pending |
| ELECTRIC DRIVE AXLE WITH MULTI-SPEED GEARBOXB60K 1/00, F16H 3/091, B60B 35/12, B60K 1/02, B60K 17/08, B60K 17/28, B60K2001/001, F16H 37/0813, F16H2200/0021, F16H2200/0034Filed as Dana Belgium N.V.2026-05-11Kurt CATTOOR | pending |
| SYSTEM AND METHOD FOR SHIFTING TWO SPEED TRANSMISSIONB60L 15/2054, F16H 63/502, B60L2200/36, B60L2240/12, B60L2240/14, B60L2240/421, B60L2240/423, B60L2240/486, B60Y2200/91, F16H 59/46, F16H 61/0403, F16H2059/462, F16H2061/0422, F16H2061/0474Filed as DANA ITALIA S.R.L.2026-05-06Giacomo FAGGIANI | pending |
| GUIDE ASSEMBLY COMPRISING AN ELASTIC ELEMENTF16H 48/24, F16H 48/08, F16H 48/32, F16H2048/204Filed as DANA ITALIA S.R.L.2026-04-28Davide DEIMICHEI | pending |
| ELECTRIC DRIVE SYSTEM WITH POWER TAKE-OFF (PTO) AND ELECTRIC DRIVE OPERATING METHODB60K 6/365, B60K 17/28, B60K 1/02, B60K 6/387, B60K 17/08, B60K 25/06, B60K2006/4816, B60K2025/005, F16H 3/725, F16H2200/0021Filed as Dana Belgium N.V.2026-04-24Korneel BOLLE | pending |
| MACROPHAGE CARS AND USES THEREOFFiled as DANA-FARBER CANCER INSTITUTE, INC.2026-03-25CHRISTIAN BRENDEL | pending |
| METHODS, KITS AND SYSTEMS FOR DETERMINING THE TRANSCRIPTIONAL SUBTYPE OF PANCREATIC CANCER AND METHODS FOR TREATING BASED ON THE SAMEFiled as DANA-FARBER CANCER INSTITUTE, INC.2026-03-24HARSHABAD SINGH | pending |
| COMPOUNDS, COMPOSITIONS, AND METHODS FOR PROTEIN DEGRADATIONA61K 47/55, C07D 401/14, A61K 47/545, A61P 35/00, A61K 45/06, C07D 417/14Filed as DANA-FARBER CANCER INSTITUTE, INC.2026-03-12Deyao Li | pending |
| SIK INHIBITORS FOR TREATING NK LYMPHOMAFiled as DANA-FARBER CANCER INSTITUTE, INC.2026-03-09LAURIE H. GLIMCHER | pending |
| SYSTEM AND METHOD FOR CLUTCH HEATING CONTROLF16D 48/06, F16H 61/30, B60K 6/365, B60K 6/387, B60K 6/445, B60K 6/52, B60K2006/381, B60W 30/186, B60W2510/0241, B60W2510/0275, B60W2710/0666, B60W2710/083, B60Y2200/92, F16D 48/062, F16D2500/10412, F16D2500/30405, F16D2500/3065, F16H 59/00, F16H 59/36, F16H 61/0213, F16H2059/6807, F16H2059/725, F16H2200/201, F16H2306/42Filed as DANA BELGIUM2026-03-09Nicolas LENAERTS | pending |
| COMPOUNDS FOR TAU PROTEIN DEGRADATIONA61K 31/4545, G01N 33/6896, A61K 47/55, A61P 25/28, A61K 31/437, A61K 38/05, A61K 38/1709, A61K 51/0455, C07D 471/04, C07K 5/06034, C07K 14/4711, C12N 9/93, G01N 33/534Filed as Dana-Farber Cancer Institute, Inc.2026-03-09Nathanael S. Gray | pending |
| ANTIBODIES AGAINST UPAR AND METHODS OF USE THEREOFFiled as DANA-FARBER CANCER INSTITUTE, INC.2026-03-05WAYNE A. MARASCO | pending |
| GEAR BOX WITH LUBRICATION CHANNELB60K 7/0007, F16H 57/0424, B60K 17/043, B60K 17/046, B60K2007/0061, F16H 57/027, F16H 57/03, F16H 57/0416, F16H 57/045, F16H 57/0457, F16H 57/0471, F16H 57/0495Filed as DANA (WUXI) TECHNOLOGY CO., LTD.2026-02-09Pradip JASUD | pending |
| METHODS AND COMPOSITIONS FOR RECONSTITUTING MICROGLIAA61K 35/28, C07K 14/7158, A61P 25/00, A61K 31/255, A61K 35/30, A61K 38/00, C12N 5/0622, C12N 15/90, C12N2506/11, C12N2510/00, A61K2300/00Filed as Dana-Farber Cancer Institute, Inc.2026-02-06Alessandra Biffi | pending |
| STABILIZED PEPTIDES FOR COVALENT BINDING TO TARGET PROTEINC07K 7/08, C07K 14/001, C07K 14/00, G01N 30/72, G01N 33/6803, G01N 33/6845, G01N2030/8831Filed as Dana-Farber Cancer Institute, Inc.2026-02-03Loren D. Walensky | pending |
| MDM2-BASED DEGRADERS TARGETING CDK9Filed as DANA-FARBER CANCER INSTITUTE, INC.2026-02-02SAMANTHA BEVILL | pending |
| STAPLED ANTIMICROBIAL PEPTIDES AND USES THEREOFFiled as DANA-FARBER CANCER INSTITUTE, INC.2026-01-23GREGORY H. BIRD | pending |
| RECEPTOR-MEDIATED ENDOCYTOSIS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS WITH LOW OFF-TARGET EFFECTSFiled as DANA-FARBER CANCER INSTITUTE, INC.2026-01-23XIN ZHOU | pending |
| NON-CANONICAL PEPTIDE ANTIGENS AS THERAPEUTIC TARGETS IN CANCERFiled as DANA-FARBER CANCER INSTITUTE, INC.2026-01-21WILLIAM A. FREED-PASTOR | pending |
| HYBRID ELECTRIC AXLE AND OPERATING METHODB60K 6/387, B60K 6/48, B60K 6/365, B60K 6/383, B60K 6/40, B60K 6/405, B60K 6/52, B60K2006/4808, B60K2006/4825, B60K2006/4833, Y02T 10/62Filed as Dana Automotive Systems Group, LLC2026-01-20Eric M. Engerman | pending |
| ELECTRIC MACHINE WITH STATOR RETENTION SYSTEMH02K 1/18, H02K 1/185, H02K 15/40, H02K 5/24, H02K 15/02Filed as DANA TM4 INC.2026-01-16Benjamin POWELL | pending |
| MODULATED OVERCURRENT LEVEL FOR VARIABLE GATE DRIVE STRENGTHH02M 1/0009, H02M 1/32, B60L 50/51, H02M 1/0029, B60L 15/007, B60L2240/525, B60L2240/529, H02M 1/08, H02M 7/5387Filed as DANA TM4 INC.2026-01-12Pascal FLEURY | pending |
| SYSTEMS FOR POWER MODULE PACKAGINGH10W 74/114, H05K 1/181, H10W 72/823, H10W 74/127, H10W 70/60, H05K2201/10287, H05K2201/10977, H05K2201/2072Filed as DANA TM4 ITALIA S.R.L.2026-01-09Pierpaolo ZULPO | pending |
| METHODS OF TREATING CANCERSA61P 35/00, A61K 31/506, C12N2310/20, G01N 33/57595, A61K 31/423, A61K 31/4439, A61K 31/444, A61K 31/454, A61K 31/713, A61K 38/00, A61K 38/1761, A61K 38/45, A61K 39/3955, A61K 45/06, C07K 16/40, C07K2317/24, C07K2317/54, C07K2317/55, C12N 15/1137, C12N2310/11, C12N2310/14, C12Y 203/02, C12Y 304/19012, G01N2800/52Filed as Dana-Farber Cancer Institute, Inc.2026-01-07Alan D. D'ANDREA | pending |
| CLDN18.2-TARGETING CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USEFiled as DANA-FARBER CANCER INSTITUTE, INC.2026-01-07ERIC LAWRENCE SMITH | pending |
| IDENTIFICATION OF SOMATIC OR GERMLINE ORIGIN FOR CELL-FREE DNAG16B 20/20, G16B 20/10, G06N 3/123, G16H 50/70, G16H 50/20, G16B 30/10, G16B 30/20, G16B 40/20, C12Q 1/6869, C12Q 1/6886, C12Q2600/106, C12Q2600/156Filed as Dana-Farber Cancer Institute, Inc.2026-01-06Richard B. LANMAN | pending |
| COMPRESSION SEALING FOR STATOR COOLINGH02K 1/185, H02K 5/10, H02K 3/24, H02K 5/24, H02K 9/197Filed as DANA TM4 INC.2025-12-29Carl TRUDEL | pending |
| SYNTHESIS AND IN VITRO CHARACTERIZATION OF PROTEOLYSIS TARGETING CHIMERAS (PROTACS) FOR DEGRADATION OF DNA METHYLTRANSFERASE 1 (DNMT1)C07D 471/04, A61P 35/00, A61K 31/4545, A61K 31/519, C07D 401/14, C07D 417/14Filed as DANA-FARBER CANCER INSTITUTE, INC.2025-12-23Jun QI | pending |
| Compositions Comprising Neural Precursor Cell Expressed, Developmentally Down-Regulated 9 (NEDD9)-Binding Peptides and Methods of Use ThereofC07K 7/08, A61P 9/12, A61P 35/00, A61K 38/00, C07K 7/06Filed as DANA-FARBER CANCER INSTITUTE, INC.2025-12-22Bradley A. Maron | pending |
| RECEPTOR-MEDIATED ENDOCYTOSIS FOR TARGETED INTERNALIZATION OF C-C CHEMOKINE RECEPTOR 6Filed as DANA-FARBER CANCER INSTITUTE, INC.2025-12-22XIN ZHOU | pending |
| BIOORTHOGONALLY DEGRADABLE TOUGH HYDROGELSFiled as DANA-FARBER CANCER INSTITUTE, INC.2025-12-19JUSTIN KIM | pending |
| METHODS OF TREATING CHRONIC LYMPHOCYTIC LEUKEMIAA61K 31/5377, A61P 35/02, A61K 31/4178, A61K 31/44, A61K 31/4709, A61K 31/4745, A61K 31/497, A61K 31/517, A61K 31/553Filed as DANA-FARBER CANCER INSTITUTE, INC.2025-12-17Anthony Letai | pending |
| VHH POLYPEPTIDES THAT BIND TO MESOTHELIN, COMPOSITIONS AND METHODS OF USE THEREOFA61P 35/00, C07K 16/28, A61K2239/13, A61K2239/22, A61K2239/17, A61K 40/4202, A61K 40/31, A61K 40/11, A61K 35/17, A61K2039/505, C07K 14/7051, C07K 14/70517, C07K 14/70521, C07K 16/30, C07K2317/22, C07K2317/565, C07K2317/567, C07K2317/569, C07K2317/92, C12N 5/0636, C12N2510/00Filed as Dana-Farber Cancer Institute, Inc.2025-12-10Robert Manguso | pending |
| COMPOSITIONS AND METHODS FOR IDENTIFICATION OF VHH ANTIBODIES THAT BIND A TARGET ANTIGENC07K 16/00, C12N 15/1037, A61P 35/00, A61K2239/13, A61K2239/55, A61K2239/59, A61K 40/4255, A61K 40/31, A61K 40/11, G01N 33/5758, C07K 14/7051, C07K 14/70521, C07K 16/30, C07K2317/22, C07K2317/569, C07K2319/70, C12N 9/1211, C12N 15/1082, C12N 15/1086, C12N2740/15041, C12Y 207/01021, C40B 30/04, C40B 30/06, G01N2500/10Filed as Dana-Farber Cancer Institute, Inc.2025-12-10Robert Manguso | pending |
| SIK INHIBITORS FOR TREATING NK LYMPHOMAFiled as Dana-Farber Cancer Institute, Inc.2025-12-05Laurie H. Glimcher | pending |
| SYSTEMS FOR AN ELECTRIC MOTORH02K 3/50, H02K 5/225, H02K 5/10, H02K2203/09Filed as DANA TM4 INC.2025-12-03Simon BAKER-OSTIGUY | pending |
| IN SITU GENE EDITINGA61K 48/00, C12N 15/86, C12N 15/90, C12N2310/20, C12N 9/226, A61K 9/0019, C12N 7/00, C12N 9/22, C12N 15/102, C12N 15/11, C12N 15/113, C12N 15/907, C12N2750/14143, C12N2750/14171, C12N2800/80Filed as Dana-Farber Cancer Institute, Inc.2025-12-01Amy J. Wagers | pending |
| SIK INHIBITORS FOR TREATING NK LYMPHOMAFiled as Dana-Farber Cancer Institute, Inc.2025-12-01Laurie H. Glimcher | pending |
| Snap Fit Shelf TalkerG09F 3/204, G09F 3/208Filed as Dana Industries Inc.2025-11-29John Ricci | pending |
| BISPECIFIC ANTIBODIES FOR TREATING CANCERFiled as DANA-FARBER CANCER INSTITUTE, INC.2025-11-26WAYNE A. MARASCO | pending |
| ENGINEERED CELLS AND USES THEREOF FOR TREATING CANCERFiled as DANA-FARBER CANCER INSTITUTE, INC.2025-11-26WAYNE A. MARASCO | pending |
| IMMUNOGENIC PEPTIDES SPECIFIC TO BCMA AND TACI ANTIGENS FOR TREATMENT OF CANCERA61K 38/212, A61P 35/00, A61K2039/812, A61K 39/001117, A61K 40/4215, A61K 40/11, A61K 35/17, A61K 38/193, A61K 38/217, A61K 39/39, A61K 39/3955, A61K 39/39558, A61K2039/5154, A61K2039/55544, A61K2039/55566, A61K2039/572, C07K 7/06, C07K 14/70578, C07K 16/2803, C07K 16/2878, C07K2317/75, C07K2317/76, C12N 5/0638, A61K2300/00Filed as Dana-Farber Cancer Institute, Inc.2025-11-25Jooeun Bae | pending |
| METHODS OF CANCER DETECTION USING EXTRAEMBRYONICALLY METHYLATED CPG ISLANDSG16B 20/10, C12Q 1/6886, G16B 40/20, C12Q 1/6869, C12Q2600/154, C12Q2537/164Filed as Dana-Farber Cancer Institute, Inc.2025-11-21Jiantao Shi | pending |
| UNIVERSAL EARLY CANCER DIAGNOSTICSC12Q 1/6886, C12N2310/20, A61P 35/00, C12N 15/102, C12Q2600/154, G01N2800/52Filed as Dana-Farber Cancer Institute, Inc.2025-11-21Alexander Meissner | pending |
| ROTOR ASSEMBLIES WITH FLEXIBLE SHAFT INTERFACESH02K 11/30, H02K 1/28, H02K 7/003Filed as DANA TM4 INC.2025-11-17Rafaël BÉDARD | pending |
| REGULATORY ELEMENTS AND IMMUNE CELLSFiled as DANA-FARBER CANCER INSTITUTE, INC.2025-11-14ERIC L. SMITH | pending |
| CD4+ CYTOTOXIC T CELLS AND METHODS OF USE THEREOFA61P 35/00, C12N 5/0638, A61K 40/42, A61K 40/11, A61K 9/0019, A61K 35/17, A61K 39/00, A61K2039/5158, C07K 14/70539, C12N 5/0087, C12N2501/2302, C12N2501/24, C12N2501/599, C12N2502/1107, C12N2502/1114, C12N2502/30, C12N2502/99, C12N2506/11, C12N2510/00Filed as Dana-Farber Cancer Institute, Inc.2025-11-10Baochun Zhang | pending |
| GENOMIC PROFILING OF CELLS TO MONITOR MINIMUM RESIDUAL DISEASEFiled as DANA-FARBER CANCER INSTITUTE, INC.2025-11-04IRENE GHOBRIAL | pending |
| COMBINATIONS WITH SIK INHIBITORS FOR TREATING NK LYMPHOMAFiled as Dana-Farber Cancer Institute, Inc.2025-11-02Laurie H. Glimcher | pending |
| STAPLED BAD BH3 HELICES THAT TARGET BCL-2 MUTANTS THAT CAUSE CANCER RESISTANCE TO VENETOCLAXFiled as DANA-FARBER CANCER INSTITUTE, INC.2025-10-30LOREN D. WALENSKY | pending |
| CAR-ENHANCER PLATFORM TO ENHANCE THE FUNCTIONALITY OF IMMUNE CELLSFiled as DANA-FARBER CANCER INSITUTE, INC.2025-10-30MOHAMMAD RASHIDIAN | pending |
| COMBINATION OF USP48 INHIBITORS AND DNMT1 INHIBITORS FOR USE IN CANCER THERAPYFiled as DANA-FARBER CANCER INSTITUTE, INC.2025-10-28KIMBERLY STEGMAIER | pending |
| Methods of Treating Red Blood Cell DisordersC07K 16/244, A61P 7/00, A61P 35/02, G01N 33/57505, A61K 45/06, A61K2039/505, C07K2317/76, G01N2800/22, G01N2800/52Filed as Dana-Farber Cancer Institute, Inc.2025-10-28Laurie H. Glimcher | pending |
| DIAMINOTRIAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOFFiled as DANA-FARBER CANCER INSTITUTE, INC.2025-10-24JOHN MICHAEL HATCHER | pending |
| TREATMENT OF NON-SMALL CELL LUNG CANCERFiled as Dana-Farber Cancer Institute, Inc.2025-10-20Matthew MEYERSON | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on DAN
Company overviewEverything on DAN in one place, with the price.SEC filingsWhat DAN's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat DAN's own officers and directors buy and sell.Who owns itEvery manager reporting a position in DAN.Funds holding itWhich funds and ETFs hold DAN, and how big a bet.LobbyingWhat DAN spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on DAN's account, and who they worked for.Federal contractsWhat federal agencies pay DAN.